Stay up to date with the latest news from Cisterna, from new product launches and partnerships to milestones and what we're building next.
Cisterna Biologics has successfully completed an NSF SBIR Phase I project, demonstrating for the first time that yeast-engineered mRNA can be selectively purified and can drive protein expression in human cells, laying the groundwork for a scalable and cost-effective approach to non-immunogenic mRNA manufacturing.
